A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use. (April 2016)

• Record Type: Journal Article
• Authors: Baird, Phylicia; Leung, Sam; Hoang, Huy; Babalola, Olawumi; Devoe, Craig E; Wanchoo, Rimda; Jhaveri, Kenar D
• Is Part Of: Journal of oncology pharmacy practice. Volume 22:Number 2(2016:Jun.)
• Page Start: 357
• Page End: 360
• Publication Date: 2016-04
• Subjects: Onconephrology -- pomalidomide -- myeloma -- renal failure -- crystal nephropathy; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155214568581
• Languages: English
• ISSNs: 1078-1552

Abstract

Pomalidomide is an analog of thalidomide with immunomodulatory, anti-angiogenic, and anti-neoplastic activity indicated for the treatment of multiple myeloma refractory to at least two prior therapies. The incidence for renal failure was <5% in a single phase II study of pomalidomide and dexamethasone in patients with multiple myeloma that failed both lenalidomide and bortezomib therapy. We report a case suggesting crystal nephropathy as the mechanism for acute kidney injury in pomalidomide and fluoroquinolone use.